Literature DB >> 25362251

Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome without impulse control disorder or drug abuse.

Yasushi Shimo1, Asuka Nakajima, Nobutaka Hattori.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25362251     DOI： 10.1007/s10072-014-1996-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  10 in total

1.  Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome.

Authors:  Benjamin J Dorfman; Melissa J Nirenberg
Journal:  Parkinsonism Relat Disord       Date:  2012-06-29       Impact factor: 4.891

2.  Major depression after withdrawing dopamine agonists in two patients with restless legs syndrome and impulse control disorders.

Authors:  Claire Launois; Smaranda Leu-Semenescu; Agnès Brion; Isabelle Arnulf
Journal:  Sleep Med       Date:  2013-05-25       Impact factor: 3.492

3.  Dopamine agonist withdrawal syndrome (DAWS) in a patient with a microprolactinoma.

Authors:  Benedetta Demartini; Lucia Ricciardi; Alexandra Ward; Mark J Edwards
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-09-27       Impact factor: 10.154

4.  Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.

Authors:  Margarita Pondal; Connie Marras; Janis Miyasaki; Elena Moro; Melissa J Armstrong; Antonio P Strafella; Binit B Shah; Susan Fox; L K Prashanth; Nicolas Phielipp; Anthony E Lang
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-08-29       Impact factor: 10.154

5.  Comparison of REM sleep behaviour disorder variables between patients with progressive supranuclear palsy and those with Parkinson's disease.

Authors:  Takashi Nomura; Yuichi Inoue; Hiroshi Takigawa; Kenji Nakashima
Journal:  Parkinsonism Relat Disord       Date:  2011-11-23       Impact factor: 4.891

Review 6.  From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease.

Authors:  Mark J Millan
Journal:  Pharmacol Ther       Date:  2010-06-26       Impact factor: 12.310

7.  Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum.

Authors:  J F Chen; V J Aloyo; B Weiss
Journal:  Neuroscience       Date:  1993-06       Impact factor: 3.590

8.  Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain.

Authors:  O Chernoloz; M El Mansari; P Blier
Journal:  Neuropsychopharmacology       Date:  2008-08-06       Impact factor: 7.853

9.  Dopamine agonist withdrawal syndrome in Parkinson disease.

Authors:  Christina A Rabinak; Melissa J Nirenberg
Journal:  Arch Neurol       Date:  2010-01

10.  Addiction is a Reward Deficit and Stress Surfeit Disorder.

Authors:  George F Koob
Journal:  Front Psychiatry       Date:  2013-08-01       Impact factor: 4.157
  10 in total
  1 in total

1.  Increased Risk for New-Onset Psychiatric Adverse Events in Patients With Newly Diagnosed Primary Restless Legs Syndrome Who Initiate Treatment With Dopamine Agonists: A Large-Scale Retrospective Claims Matched-Cohort Analysis.

Authors:  Cheryl Hankin; Daniel Lee; Diego Garcia-Borreguero; Zhaohui Wang
Journal:  J Clin Sleep Med       Date:  2019-09-15       Impact factor: 4.062
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.